Vomiting Bug Vaccine Seen as Shot in the Arm for Cruises: Health - Businessweek
Early stage human studies on a vaccine against norovirus, the top source of gastroenteritis in the U.S., are set to finish this year. That would make work on the vaccine, developed by Takeda Pharmaceutical Co. (4502), the farthest along of several immunization candidates. A course of shots may confer lifelong protection against 95 percent of strains, said Rajeev Venkkaya, who heads the Japanese drugmaker’s vaccines unit.
Aucun commentaire:
Enregistrer un commentaire